A team of biotech veterans say they have raised $3 billion to create a continent-spanning company that will aim to battle disease by reprogramming the fundamental machinery of living cells.
It appears to be the largest venture capital fundraising effort in biotech history, based on a survey of data from Pitchbook.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
